Search Results

You are looking at 1 - 10 of 33 items for :

  • GHD in adults x
  • Open access x
Clear All
Open access

Johan Verhelst, Anders F Mattsson, Cecilia Camacho-Hübner, Anton Luger, and Roger Abs

881 – 889 . ( https://doi.org/10.1530/EJE-11-0599 ) 21969523 10.1530/EJE-11-0599 4 Claessen KM Appelman-Dijkstra NM Adoptie DM Roelfsema F Smit JW Biermasz NR Pereira AM. Metabolic profile in growth hormone-deficient (GHD) adults

Open access

Charlotte Höybye, Erik Wahlström, Petra Tollet-Egnell, and Gunnar Norstedt

replacement therapy with thyroxin, hydrocortisone, sex steroids, and vasopressin for at least 2 years. The characteristics of the patients are given in Table 1 . All had adult-onset GHD, and had not previously been treated with GH. None of the patients had

Open access

M Ahmid, C G Perry, S F Ahmed, and M G Shaikh

) has been estimated to be about 1 in 3500–4000 live births, whereas the prevalence of adult onset (AO-GHD) in addition to those with previous CO-GHD is also about 1 in 3000 of the UK adult population ( 1 , 2 ). In addition to linear growth, the GH

Open access

Charlotte Höybye, Laia Faseh, Christos Himonakos, Tomasz Pielak, and Jesper Eugen-Olsen

and GH treatment on low-grade inflammation and the level of suPAR in patients with GHD are unknown. The primary aim of this study was to establish baseline suPAR levels in a cohort of adults with GHD. The secondary aims were to measure suPAR during

Open access

Ursula M M Costa, Carla R P Oliveira, Roberto Salvatori, José A S Barreto-Filho, Viviane C Campos, Francielle T Oliveira, Ivina E S Rocha, Joselina L M Oliveira, Wersley A Silva, and Manuel H Aguiar-Oliveira

synergistic anabolic effect on muscle mass, but antagonist effects on insulin action (GH-reducing and IGF1 increasing insulin sensitivity) and lipolysis (GH increasing and IGF1 reducing it) (2) . Adult onset GH deficiency (GHD) has been described as model of

Open access

Mark R Postma, Pia Burman, and André P van Beek

areas that are affected in adults with GHD ( 24 ). The measure consists of 25 questions with ‘yes’ or ‘no’ response choices, with ‘yes’ answer indicating that the patient perceives a problem. The sum of ‘yes’ responses constitute a score, with a high

Open access

Kennett Sprogøe, Eva Mortensen, David B Karpf, and Jonathan A Leff

acceptable PK and pharmacodynamic (PD) profiles in adults with GHD following once-weekly administration ( 29 ). However, a satisfactory IGF-1 profile was not achieved in children with GHD ( 30 ), and as a result, development was discontinued ( 31 , 32

Open access

Anastasia Ibba, Francesca Corrias, Chiara Guzzetti, Letizia Casula, Mariacarolina Salerno, Natascia di Iorgi, Gianluca Tornese, Giuseppa Patti, Giorgio Radetti, Mohamad Maghnie, Marco Cappa, and Sandro Loche

onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults . Journal of Clinical Endocrinology and Metabolism 1999 84 1324 – 1328 . ( https://doi.org/10.1210/jcem.84.4.5614 ) 44 Rosenfeld RG

Open access

Thomas Reinehr, Martin Carlsson, Dionisios Chrysis, and Cecilia Camacho-Hübner

height is lower than predicted height. The difference between predicted and achieved adult height depends on bone age retardation in CDGP ( 8 , 9 , 11 ). Since bone age is delayed in children with growth hormone deficiency (GHD) before the initiation

Open access

Laura van Iersel, Sarah C Clement, Antoinette Y N Schouten-van Meeteren, Annemieke M Boot, Hedi L Claahsen-van der Grinten, Bernd Granzen, K Sen Han, Geert O Janssens, Erna M Michiels, A S Paul van Trotsenburg, W Peter Vandertop, Dannis G van Vuurden, Hubert N Caron, Leontien C M Kremer, and Hanneke M van Santen

prevalence and latency times of cRT-induced HP dysfunction vary among patients, with growth hormone deficiency (GHD) usually occurring first and at a prevalence ranging from 29.0 to 39.1% ( 3 ). In contrast, central hypothyroidism primarily occurs after high